Japanese Pharma Consolidation: What Should It Mean For Your Partnering Strategy
Tuesday, January 20, 2009
9:15 am - 10:30 am
Tarragon Room
The past 5 years has seen a remarkable wave of consolidation in the Japanese pharma industry. This re-ordering of the players in the industry means that while there are fewer players, those that remain have greater resources and ability to conduct business on a global scale. As a result of these changes, though, should emerging biotech firms adjust their partnering and alliance strategies? How should these companies approach the “new” Japanese industry? Should they have concerns that a potential partner might be acquired or merged? This panel will discuss these considerations.
Moderator:
- David Flores Co-Founder, President & CEO, BioCentury Publications, Inc.
Panelists:
- Dr. Shingo Kano, CEO, Aphoenix, Inc.
- Dr. Nobuo Kato, Vice-President & COO, Y’s Therapeutics
- Arlene M. Morris, President and CEO, Affymax, Inc.
- Kyle Murphy, Managing Director, KMG Japan Inc.
- Axel Takeshi Wellbrock, Director Strategic Planning and Business Development, AstraZeneca KK Japan